|
Pt
|
Sex
|
Onset age (years) (岁)
|
Final diagnosis
|
Treatment
|
Time of CAD recovery
|
Duration of follow-up (month)
|
Result
|
|---|
|
1
|
F
|
10.5
|
CAEBV
|
L-DEP
|
Non-recovered
|
8.0
|
Alive
|
|
2
|
M
|
6.3
|
CAEBV
|
Abandon
|
Non-recovered
|
12.0
|
Alive
|
|
3
|
M
|
12.2
|
CAEBV, HLH
|
Abandon
|
Non-recovered
|
13.0
|
Alive
|
|
4
|
F
|
5.8
|
CAEBV
|
Abandon
|
Non-recovered
|
27.0
|
Alive
|
|
5
|
M
|
14.3
|
CAEBV
|
L-DEP
|
18 days
|
28.0
|
Alive
|
|
6
|
M
|
3.2
|
CAEBV
|
L-DEP, HSCT
|
68 days
|
28.0
|
Alive
|
|
7
|
M
|
7.6
|
CAEBV
|
L-DEP, HSCT
|
Non-recovered
|
6.0
|
Dead
|
|
8
|
F
|
4.3
|
CAEBV
|
L-DEP, HSCT
|
Non-recovered
|
48.0
|
Alive
|
|
9
|
F
|
2.8
|
CAEBV,HLH
|
L-DEP
|
Non-recovered
|
8.0
|
Alive
|
|
10
|
M
|
5.0
|
CAEBV, HLH
|
L-DEP, HSCT
|
21 days
|
30.0
|
Alive
|
- Pt patient, CAEBV chronic active Epstein–Barr virus infection, HLH hemophagocytic lymphohistiocytosis, CAD coronary artery dilatation, L-DEP PEG-Aspegaspargase, doxorubicin, etoposide and methylprednisolone, time of CAD recovery the time from discovery of CAD to recovery
